Αρχική World News FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma

FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma

On 18 June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumours are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.

The FDA also approved the cobas EZH2 Mutation Test (Roche Molecular Systems, Inc.) as a companion diagnostic for tazemetostat.

Approval was based on two open-label, single-arm cohorts (Cohort 4 – EZH2 mutated FL and Cohort 5 – EZH2 wild-type FL) of a multicentre trial (Study E7438-G000-101, NCT01897571) in patients with histologically confirmed FL after at least 2 prior systemic therapies. EZH2 mutations were identified prospectively using formalin-fixed, paraffin-embedded tumour samples, which were centrally tested using the cobas® EZH2 Mutation Test. Patients received tazemetostat 800 mg orally twice daily until confirmed disease progression or unacceptable toxicity.

Efficacy was based on overall response rate (ORR) and duration of response (DoR) according to the International Working Group Non-Hodgkin Lymphoma criteria as assessed by an independent review committee. The ORR in 42 patients with EZH2 mutant FL was 69% (95% confidence interval [CI] 53%, 82%), with 12% complete responses and 57% partial response. Median DoR in these patients was 10.9 months (95% CI 7.2, NE). The ORR in 53 patients with EZH2 wild-type FL was 34% (95% CI 22%, 48%), with 4% complete responses and 30% partial responses. Median DoR was 13 months (95% CI 5.6, NE).

The most common (≥20%) adverse reactions in patients with follicular lymphoma included fatigue, upper respiratory tract infection, musculoskeletal pain, nausea and abdominal pain. Serious adverse reactions occurred in 30%, most often from infection. Second primary malignancy was the most common reason for treatment discontinuation (2% of patients). The prescribing information includes a warning and precaution for secondary malignancies.

The recommended tazemetostat dose is 800 mg taken orally twice daily with or without food.

Full prescribing information for TAZVERIK is available here.

These indications are approved under accelerated approval based on ORR and DoR. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

This application was granted priority review and Fast Track designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...
- Advertisment -

Ροή Ειδήσεων

Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’

Rena Williams radiates positivity and joy. According to friends, family, and coworkers, this has always been true of Rena, and she wasn’t about to...

Coronavirus reports – Part 9: “I am very relieved but I am not naïve”

Max and his wife We caught up with people living with cancer across the country, to find out how the coronavirus pandemic has been affecting...

Answers to Your Questions About the COVID-19 Vaccine

Julie Gralow, MD, FACP, FASCO, is the Chief Medical Officer (CMO) and Executive Vice President of the American Society of Clinical Oncology (ASCO). Previously, she...

The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That Has Educated Us

In April of 2007, OncoLink launched the OncoLife Survivorship Care Plan, a tool to create care plans for people who have survived cancer. As...

EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab

On 25 February 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change...

Daughter Donates Hair to Mother After She Was Diagnosed with Stage IV Breast Cancer

Marybeth Kersey has wanted to donate her hair to her mother, Lynn Hier, since she first found out she had stage I breast cancer....